Replies to post #199784 on Avid Bioservices Inc (CDMO)

[biopharm]

Sonia Perez (Head of Immune Monitoring Lab at Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital) seems to have a good working relationship with Nikoletta who left the East Coast to all of a sudden jump at an opportunity at Peregrine on the West Coast and looks to have global demand plans for Bavituximab.

Yes Biopharm, Sonia seems to know much about Bavituximab and PS Targeting now. Maybe she advised Nikoletta that it would be a very good career move to get into Peregrine before the SunRises and everyone sees what is going on and how important PS Targeting will be for medical treatment. I could highlight most of this in red below... but biopharm, you are on the right track.

-----------------------

CIIC: Developing Promising New Therapies

Founded in 1996, the Cancer Immunology and Immunotherapy Center St. Savvas Hospital (CIIC) in Athens focuses on advanced research in cellular immunology, molecular immunology, cellular cancer immunology, cancer drug targets, gene cancer therapy, and the production of monoclonal antibodies to tumor-associated antigens. The center is headed by Dr. Michael Papamichail (photo), who leads a team of 15 scientists as they investigate how the body's immune system can be mobilized against cancer.

The center has been instrumental in furthering this field of study, which provides a basis for the development of cancer immunotherapy. According to Dr. Papamichail, his team has made outstanding progress, and its research should soon yield positive results for the treatment of cancer and other diseases.

CIIC actively cooperates with a number of leading research institutions in Europe and the United States, with the overall goal of translating basic scientific research into clinical applications. The center collaborates with Nottingham Trent University in the UK, with Germany's Cancer Research Center of Heidelberg, with the Danish Cancer Center, and with the Karolinksa Institute in Stockholm.

"The center seeks out the best and the brightest young scientists. Greece has a wealth of intellectual capital, and many scientists are willing to work long hours to achieve important results. I am encouraged by the efforts of my team and am sure that our work will be recognized as some of the most progressive being done today."

Current research at the center that shows great promise for the near future includes stem cell therapy for myocardial infarction (heart disease) and innovative approaches to cancer immunotherapy. Myocardial infarction is a major cause of adult death throughout the world. The CIIC laboratory has isolated human mesenchymal stem cells (MSC) from bone marrow. The team has initiated a clinical trial to investigate the possibility that a combination of MSC and endothelial stem cells (those cells that contribute to a generation of new blood vessels) can provide a novel and permanent therapy for acute myocardial infarction. According to Dr. Papamichail, preliminary results are very encouraging and the center is in the process of initiating a clinical trial involving infusion of MSC with bone marrow for bone marrow transplants in cancer patients. Other clinical trials to be initiated in the near future include the use of MSC in lung disorders such as cystic fibrosis and in osteoporosis. In addition, it is possible that the therapy will prove beneficial for the treatment of spinal cord injury, stroke, and ALS.

Cancer immunotherapy research offers promising results for treating a variety of cancers, and the center is working on number of possible treatments. The center's Associate Director, Costas Baxevanis, Ph.D., says that CIIC has progressed, in cooperation with other European research centers, in developing new and alternative treatments that will be more effective and produce fewer side effects than some current therapies. For instance, the center is developing a therapy that targets macromolecules solely on the outer membranes of tumor cells to deliver drugs as an alternative to traditional chemotherapy or radiotherapy, both of which target normal cells in addition to tumorous cells, and create serious side effects.

Researcher Sonia Perez, Ph. D., notes that other cancer immunotherapy research includes antibody-based therapies, targeting tumor cells with chimeric receptor cells, using vaccines as cancer therapy, and identifying cell progenitors in bone marrow and cord blood. These progressive therapies may alter the current course of cancer treatment with therapies that are based on the premise that the body's immune system can be mobilized against cancer.

Dr. Papamichail is confident that the work done at CIIC will soon yield significant results. "The center," he says, "seeks out the best and the brightest young scientists. Greece has a wealth of intellectual capital, and many scientists are willing to work long hours to achieve important results. I am encouraged by the efforts of my team and am sure that our work will be recognized as some of the most progressive being done today. Our collaboration with institutions from outside Greece is a complete win-win situation, and I look forward to continued and new cooperation."

http://www.investingreece.gov.gr/newsletter/newsletter.asp?nid=84&id=123&lang=1

[PhoenixRising]

I really intend no offense but seriously,you have touted,IMO,yes touted Soon-Shiong as the brilliant one who would/should/must(?) know about PPHM/Bavi and why not throw his backing towards us as he is right on the cutting edge of our knowledge all things Bavi. Now that it APPEARS he has possibly moved on to someone else you are going to bring up Sonia Perez ad nauseum because of some more puzzle pieces? You respond to yourself while changing lanes and basically claim it's just as well Soon-Shiong has moved on(who needs him?). If someone with that much clout,as you claim,has possibly moved on from PPHM I DO NOT think that will expedite other brilliant minds to MOVE IN. Maybe you know better but I would have been happier if he had not moved on but moved in. GL PR